Results 11 to 20 of about 4,266 (228)
Romosozumab and cardiovascular safety in Japan
Osteoporosis and Sarcopenia, 2021 Romosozumab is a potent pharmacological tool to prevent fractures in osteoporosis patients, and its mechanism of action is distinct from any other drugs. The efficacy of romosozumab to prevent osteoporotic fractures is remarkable.
Yasuhiro Takeuchi
exaly +7 more sources
Romosozumab for the treatment of osteoporosis
Osteoporosis and Sarcopenia, 2018 Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality ...
Michael R Mcclung
exaly +8 more sources
Skeletal responses to romosozumab after 12 months of denosumab
JBMR Plus, 2021 Romosozumab, a monoclonal anti‐sclerostin antibody that has the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months.
Michael R Mcclung +2 more
exaly +3 more sources
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
New England Journal of Medicine, 2016 Background: Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. Methods: We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients
Crittenden, Daria B. +16 more
core +5 more sources
J Clin Endocrinol MetabContext: Trabecular bone score (TBS), a gray-level texture index derived from lumbar spine (LS) dual-energy x-ray absorptiometry (DXA) scans, is decreased in patients with diabetes and is associated with increased fracture risk, independent of areal bone
Ferrari S +7 more
europepmc +3 more sources
Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa
Osteoporosis and Sarcopenia, 2023 Objectives: This study aims to investigate the effects of romosozumab on bone mineral density (BMD) and bone metabolism. Methods: In this retrospective case series, romosozumab was administered to 5 premenopausal female patients with osteoporosis and ...
Kazuki Fujimoto +6 more
doaj +2 more sources
Comparative Analysis of Romosozumab Versus Vertebroplasty With Denosumab: Efficacy, Safety, and Secondary Bone Mineral Density Outcomes [PDF]
NeurospineObjective This study aimed to compare the efficacy and safety of romosozumab, a bone anabolic agent, versus vertebroplasty, a conventional surgical intervention, in treating osteoporotic vertebral compression fractures (OVCFs).
Hyun Woong Mun +5 more
doaj +3 more sources
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals [PDF]
JBMR Plus, 2021 Increases in bone mineral density (BMD) with osteoporosis treatment are associated with reduced fracture risk. Increasing BMD is therefore a goal of osteoporosis therapy.
Felicia Cosman +11 more
doaj +2 more sources
Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
Women's Health, 2022 Increased understanding of the Wnt signaling pathway has led to the development of romosozumab, one of the most potent osteoanabolic agents to date for osteoporosis treatment.
Siân Yik Lim
exaly +2 more sources
Romosozumab-associated medication-related osteonecrosis of the jaw
Oral and Maxillofacial Surgery Cases, 2023 This is the first reported case of medication-related osteonecrosis of the jaw (MRONJ) resulting from the use of romosozumab, a new anti-resorptive medication that functions through inhibition of sclerostin.
Benjamin Palla +4 more
doaj +2 more sources